{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:08:46Z","timestamp":1782860926494,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12216-9","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:39:39Z","timestamp":1782859179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming resistance in glioblastoma immunotherapy: lessons from the past and opportunities for the future"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5769-4509","authenticated-orcid":false,"given":"Rijhul","family":"Lahariya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-0701","authenticated-orcid":false,"given":"Mainak","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"12216_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cancers17010146","volume":"17","author":"D Sipos","year":"2025","unstructured":"Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P et al (2025) Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers 17(1):146. https:\/\/doi.org\/10.3390\/cancers17010146 PubMed PMID: 39796773; PubMed Central PMCID: PMC11719842","journal-title":"Cancers"},{"issue":"8","key":"12216_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6 PubMed PMID: 32612154; PubMed Central PMCID: PMC7395159","journal-title":"Cell Mol Immunol"},{"key":"12216_CR3","first-page":"185","volume":"17","author":"Z Sarfraz","year":"2025","unstructured":"Sarfraz Z, Maharaj A, Venur VA, Lathia JD, Odia Y, Ahluwalia MS (2025) Immunotherapy in Glioblastoma: An Overview of Current Status. Clin Pharmacol Adv Appl 17:185. 102147\/CPAA.S497903 PubMed PMID: 40735070","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"5","key":"12216_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/cancers17050817","volume":"17","author":"N Vallieri","year":"2025","unstructured":"Vallieri N, Datsi A (2025) Immune Cell Interplay in the Fight Against GBM. Cancers 17(5):817 doi:10.3390\/cancers17050817 PubMed PMID: 40075663; PubMed Central PMCID: PMC11899300","journal-title":"Cancers"},{"issue":"6","key":"12216_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","volume":"127","author":"KJ Habashy","year":"2022","unstructured":"Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ (2022) Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer 127(6):976\u2013987. https:\/\/doi.org\/10.1038\/s41416-022-01864-w","journal-title":"Br J Cancer"},{"key":"12216_CR6","doi-asserted-by":"publisher","unstructured":"Sung JY, Hwang K (2026) Breaking immune isolation in glioblastoma. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 87:101412. https:\/\/doi.org\/10.1016\/j.drup.2026.101412. PubMed PMID: 42102587","DOI":"10.1016\/j.drup.2026.101412"},{"key":"12216_CR7","doi-asserted-by":"publisher","first-page":"581012","DOI":"10.2147\/ITT.S581012","volume":"15","author":"Z Cao","year":"2026","unstructured":"Cao Z, Tong S, Wang Z, Ji C, Zhang C, Dai X et al (2026) Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies. ImmunoTargets Ther 15:581012. 102147\/ITT.S581012 PubMed PMID: 41809120; PubMed Central PMCID: PMC12970017","journal-title":"ImmunoTargets Ther"},{"issue":"3","key":"12216_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76(3):359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030 PubMed PMID: 31668929; PubMed Central PMCID: PMC6981282","journal-title":"Mol Cell"},{"key":"12216_CR9","doi-asserted-by":"publisher","unstructured":"Yang T, Kong Z, Ma W PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Hum Vaccines Immunother 17(2):546\u2013553. https:\/\/doi.org\/10.1080\/21645515.2020.1782692 PubMed PMID: 32643507; PubMed Central PMCID: PMC7899692.","DOI":"10.1080\/21645515.2020.1782692"},{"key":"12216_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C (2023) Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct Target Ther 8:450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3 PubMed PMID: 38086815","journal-title":"Signal Transduct Target Ther"},{"key":"12216_CR11","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.ebiom.2023.104963","volume":"100","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G (2024) Glioblastoma vaccines: past, present, and opportunities. eBioMedicine 100:104963. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104963 PubMed PMID: 38183840; PubMed Central PMCID: PMC10808938","journal-title":"eBioMedicine"},{"issue":"4","key":"12216_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13760-024-02519-8","volume":"124","author":"AK Das","year":"2024","unstructured":"Das AK, Sinha M, Singh SK, Chaudhary A, Boro AK, Agrawal M et al (2024) CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas. Acta Neurol Belg 124(4):1251\u20131261. https:\/\/doi.org\/10.1007\/s13760-024-02519-8","journal-title":"Acta Neurol Belg"},{"key":"12216_CR13","doi-asserted-by":"publisher","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","volume":"13","author":"MP Jogalekar","year":"2022","unstructured":"Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC (2022) CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol 13:925985. https:\/\/doi.org\/10.3389\/fimmu.2022.925985 PubMed PMID: 35936003; PubMed Central PMCID: PMC9355792","journal-title":"Front Immunol"},{"key":"12216_CR14","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.2147\/IJGM.S418837","volume":"16","author":"T Liang","year":"2023","unstructured":"Liang T, Song Y, Gu L, Wang Y, Ma W (2023) Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma. Int J Gen Med 16:4121\u20134141. https:\/\/doi.org\/10.2147\/IJGM.S418837 PubMed PMID: 37720174; PubMed Central PMCID: PMC10503554","journal-title":"Int J Gen Med"},{"key":"12216_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","volume":"9","author":"G Marelli","year":"2018","unstructured":"Marelli G, Howells A, Lemoine NR, Wang Y (2018) Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Front Immunol 9:866. https:\/\/doi.org\/10.3389\/fimmu.2018.00866 PubMed PMID: 29755464; PubMed Central PMCID: PMC5932159","journal-title":"Front Immunol"},{"issue":"6","key":"12216_CR16","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s13311-022-01256-1","volume":"19","author":"ML Shoaf","year":"2022","unstructured":"Shoaf ML, Desjardins A (2022) Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. Neurotherapeutics 19(6):1818\u20131831. https:\/\/doi.org\/10.1007\/s13311-022-01256-1 PubMed PMID: 35674873; PubMed Central PMCID: PMC9723031","journal-title":"Neurotherapeutics"},{"key":"12216_CR17","doi-asserted-by":"publisher","unstructured":"Tan Y, Chen H, Gou X, Fan Q, Chen J Tumor vaccines: Toward multidimensional anti-tumor therapies. Hum Vaccines Immunother 19(3):2271334. https:\/\/doi.org\/10.1080\/21645515.2023.2271334 PubMed PMID: 37905395; PubMed Central PMCID: PMC10760370.","DOI":"10.1080\/21645515.2023.2271334"},{"issue":"2","key":"12216_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH et al (2018) Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med 379(2):150\u2013161 doi:10.1056\/NEJMoa1716435 PubMed PMID: 29943666; PubMed Central PMCID: PMC6065102","journal-title":"N Engl J Med"},{"key":"12216_CR19","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753 PubMed PMID: 33259885; PubMed Central PMCID: PMC8084948","journal-title":"Pharmacol Ther"},{"issue":"57","key":"12216_CR20","doi-asserted-by":"publisher","first-page":"96496","DOI":"10.18632\/oncotarget.20410","volume":"8","author":"YA Lyons","year":"2017","unstructured":"Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ et al (2017) Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8(57):96496\u201396505. https:\/\/doi.org\/10.18632\/oncotarget.20410 PubMed PMID: 29228548; PubMed Central PMCID: PMC5722500","journal-title":"Oncotarget"},{"issue":"Pt 1","key":"12216_CR21","doi-asserted-by":"publisher","first-page":"117187","DOI":"10.1016\/j.bcp.2025.117187","volume":"242","author":"L Peng","year":"2025","unstructured":"Peng L, Fang Z, Zhang W, Rao GW, Zheng Q (2025) Recent advances in colony stimulating factor-1 receptor (CSF1R) inhibitors. Biochem Pharmacol 242(Pt 1):117187. https:\/\/doi.org\/10.1016\/j.bcp.2025.117187 PubMed PMID: 40721006","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"12216_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A et al (2020) Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncol 6(7):1\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024 PubMed PMID: 32437507; PubMed Central PMCID: PMC7243167","journal-title":"JAMA Oncol"},{"issue":"1","key":"12216_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T et al (2023) Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncol 25(1):123\u2013134. https:\/\/doi.org\/10.1093\/neuonc\/noac099 PubMed PMID: 35419607; PubMed Central PMCID: PMC9825306","journal-title":"Neuro-Oncol"},{"issue":"11","key":"12216_CR24","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR et al (2022) Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncol 24(11):1935\u20131949. https:\/\/doi.org\/10.1093\/neuonc\/noac116 PubMed PMID: 35511454; PubMed Central PMCID: PMC9629431","journal-title":"Neuro-Oncol"},{"key":"12216_CR25","unstructured":"PharmAbcine A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma [Clinical trial registration]. clinicaltrials.gov; 2022 Aug. Clinical trial registration no.: NCT03722342. https:\/\/clinicaltrials.gov\/study\/NCT03722342"},{"issue":"2","key":"12216_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00262-025-04226-6","volume":"75","author":"M Levite","year":"2026","unstructured":"Levite M, Ilouz N, Galun E, Shoshan Y (2026) Empowering exhausted T cells of Glioblastoma patients by Neurotransmitters and Neuropeptides: decreasing immune checkpoint inhibitors, and increasing CD3zeta, proliferation and Glioblastoma arrest. Cancer Immunol Immunother CII 75(2):54. https:\/\/doi.org\/10.1007\/s00262-025-04226-6 PubMed PMID: 41591460; PubMed Central PMCID: PMC12847560","journal-title":"Cancer Immunol Immunother CII"},{"key":"12216_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12672-026-04416-3","volume":"17","author":"Z Wang","year":"2026","unstructured":"Wang Z, Fu H, Li Y, Liu Z, Fan W, Liu Y et al (2026) Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma. Discov Oncol 17:280. https:\/\/doi.org\/10.1007\/s12672-026-04416-3 PubMed PMID: 41538103; PubMed Central PMCID: PMC12891324","journal-title":"Discov Oncol"},{"issue":"2","key":"12216_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/ijms26020669","volume":"26","author":"Y Vijayanathan","year":"2025","unstructured":"Vijayanathan Y, Ho IAW (2025) The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies. Int J Mol Sci 26(2):669. https:\/\/doi.org\/10.3390\/ijms26020669 PubMed PMID: 39859381; PubMed Central PMCID: PMC11765942","journal-title":"Int J Mol Sci"},{"issue":"10","key":"12216_CR29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373\u20131385 (17)30517-X PubMed PMID: 28844499","journal-title":"Lancet Oncol"},{"issue":"1","key":"12216_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM et al (2023) Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncol 9(1):112\u2013121. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5370 PubMed PMID: 36394838; PubMed Central PMCID: PMC9673026","journal-title":"JAMA Oncol"},{"key":"12216_CR31","doi-asserted-by":"publisher","first-page":"872756","DOI":"10.3389\/fimmu.2022.872756","volume":"13","author":"OY Tang","year":"2022","unstructured":"Tang OY, Tian L, Yoder T, Xu R, Kulikovskaya I, Gupta M et al (2022) PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Front Immunol 13:872756. https:\/\/doi.org\/10.3389\/fimmu.2022.872756 PubMed PMID: 35603165; PubMed Central PMCID: PMC9120664","journal-title":"Front Immunol"},{"key":"12216_CR32","unstructured":"Ph DGA, INTERCEPT INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM [Clinical trial registration]. clinicaltrials.gov. Clinical trial registration no.: NCT03283631. https:\/\/clinicaltrials.gov\/study\/NCT03283631"},{"issue":"1","key":"12216_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11060-026-05497-4","volume":"177","author":"J Liu","year":"2026","unstructured":"Liu J, Abikenari M, Annagiri S, Ha JH, Nageeb G, Sjoholm MA et al (2026) Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry. J Neurooncol 177(1):50. https:\/\/doi.org\/10.1007\/s11060-026-05497-4 PubMed PMID: 41820710; PubMed Central PMCID: PMC12982237","journal-title":"J Neurooncol"},{"issue":"2","key":"12216_CR34","doi-asserted-by":"publisher","first-page":"114609","DOI":"10.1016\/j.isci.2025.114609","volume":"29","author":"A Mariniello","year":"2026","unstructured":"Mariniello A, Migliorini D (2026) CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives. iScience 29(2):114609. https:\/\/doi.org\/10.1016\/j.isci.2025.114609 PubMed PMID: 41675045; PubMed Central PMCID: PMC12886550","journal-title":"iScience"},{"issue":"5","key":"12216_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/neuonc\/noz232","volume":"22","author":"TF Cloughesy","year":"2020","unstructured":"Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL et al (2020) A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncol 22(5):705\u2013717. https:\/\/doi.org\/10.1093\/neuonc\/noz232 PubMed PMID: 31844890; PubMed Central PMCID: PMC7229248","journal-title":"Neuro-Oncol"},{"key":"12216_CR36","unstructured":"Oncolytics Biotech. A Phase I\/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN\u00ae for the Treatment of Patients With Histologically Confirmed Recurrent Malignant Gliomas [Clinical trial registration]. clinicaltrials.gov. Clinical trial registration no.: NCT00528684. https:\/\/clinicaltrials.gov\/study\/NCT00528684"},{"issue":"12","key":"12216_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.3161","volume":"6","author":"TF Cloughesy","year":"2020","unstructured":"Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J et al (2020) Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol 6(12):1. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3161 PubMed PMID: 33119048","journal-title":"JAMA Oncol"},{"issue":"4","key":"12216_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY et al (2016) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncol 18(4):557\u2013564. https:\/\/doi.org\/10.1093\/neuonc\/nov245 PubMed PMID: 26449250; PubMed Central PMCID: PMC4799682","journal-title":"Neuro-Oncol"},{"issue":"28","key":"12216_CR39","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4733\u20134740 .2008.19.8721 PubMed PMID: 19720927","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"12216_CR40","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","volume":"38","author":"A Wick","year":"2020","unstructured":"Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T et al (2020) Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest New Drugs 38(5):1570\u20131579. https:\/\/doi.org\/10.1007\/s10637-020-00910-9 PubMed PMID: 32140889; PubMed Central PMCID: PMC7497674","journal-title":"Invest New Drugs"},{"issue":"1","key":"12216_CR41","doi-asserted-by":"publisher","first-page":"pgaf396","DOI":"10.1093\/pnasnexus\/pgaf396","volume":"5","author":"J Chen","year":"2026","unstructured":"Chen J, Zhu L, Lawson T, Proud CG, Dai L (2026) Role of elevation of glycolysis in tumor-associated macrophages in glioblastoma immune evasion and therapeutic implications. PNAS Nexus 5(1):pgaf396. https:\/\/doi.org\/10.1093\/pnasnexus\/pgaf396 PubMed PMID: 41567927; PubMed Central PMCID: PMC12818015","journal-title":"PNAS Nexus"},{"issue":"2","key":"12216_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/cancers18020212","volume":"18","author":"S Agarwal","year":"2026","unstructured":"Agarwal S, Han S, Lal A, Vira V, Chandla A, Mehranpour P et al (2026) A Comprehensive Review of Immunotherapeutic Modalities in Glioblastoma: Mechanisms, Efficacy, and Safety Considerations. Cancers 18(2):212. https:\/\/doi.org\/10.3390\/cancers18020212 PubMed PMID: 41595133; PubMed Central PMCID: PMC12838777","journal-title":"Cancers"},{"key":"12216_CR43","doi-asserted-by":"publisher","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","volume":"15","author":"P Ouyang","year":"2024","unstructured":"Ouyang P, Wang L, Wu J, Tian Y, Chen C, Li D et al (2024) Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front Immunol 15:1344272. https:\/\/doi.org\/10.3389\/fimmu.2024.1344272 PubMed PMID: 38545114; PubMed Central PMCID: PMC10965539","journal-title":"Front Immunol"},{"issue":"6","key":"12216_CR44","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA et al (2023) Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med 29(6):1370. https:\/\/doi.org\/10.1038\/s41591-023-02347-y PubMed PMID: 37188783","journal-title":"Nat Med"},{"key":"12216_CR45","doi-asserted-by":"publisher","unstructured":"Db K, Aj A, I JS, Nd T (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738). https:\/\/doi.org\/10.1038\/s41586-018-0792-9 PubMed PMID: 30568305","DOI":"10.1038\/s41586-018-0792-9"},{"issue":"4","key":"12216_CR46","doi-asserted-by":"publisher","first-page":"e1561106","DOI":"10.1080\/2162402X.2018.1561106","volume":"8","author":"TM Johanns","year":"2019","unstructured":"Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK et al (2019) Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology 8(4):e1561106 2018.1561106 PubMed PMID: 30906654; PubMed Central PMCID: PMC6422384","journal-title":"Oncoimmunology"},{"issue":"6","key":"12216_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/vaccines13060550","volume":"13","author":"R Han","year":"2025","unstructured":"Han R, Zhou H, Peng B, Yu S, Zhu J, Chen J (2025) Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy. Vaccines 13(6):550. https:\/\/doi.org\/10.3390\/vaccines13060550 PubMed PMID: 40573881; PubMed Central PMCID: PMC12197479","journal-title":"Vaccines"},{"issue":"23","key":"12216_CR48","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.7150\/jca.34471","volume":"10","author":"T Sun","year":"2019","unstructured":"Sun T, Li Y, Yang W, Wu H, Li X, Huang Y et al (2019) Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer 10(23):5638\u20135645. https:\/\/doi.org\/10.7150\/jca.34471 PubMed PMID: 31737100; PubMed Central PMCID: PMC6843866","journal-title":"J Cancer"},{"issue":"6","key":"12216_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","volume":"13","author":"P Zhu","year":"2023","unstructured":"Zhu P, Li SY, Ding J, Fei Z, Sun SN, Zheng ZH et al (2023) Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C. J Pharm Anal 13(6):616\u2013624. https:\/\/doi.org\/10.1016\/j.jpha.2023.04.012 PubMed PMID: 37440907; PubMed Central PMCID: PMC10334272","journal-title":"J Pharm Anal"},{"issue":"7738","key":"12216_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234\u2013239. https:\/\/doi.org\/10.1038\/s41586-018-0792-9 PubMed PMID: 30568305; PubMed Central PMCID: PMC6546179","journal-title":"Nature"},{"key":"12216_CR51","unstructured":"https:\/\/www lifescience.net. Life Science Network. Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial. https:\/\/www.lifescience.net"},{"issue":"1","key":"12216_CR52","doi-asserted-by":"publisher","first-page":"vdac185","DOI":"10.1093\/noajnl\/vdac","volume":"5","author":"A Schmidts","year":"2023","unstructured":"Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP et al (2023) Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neuro-Oncol Adv 5(1):vdac185. https:\/\/doi.org\/10.1093\/noajnl\/vdac185 PubMed PMID: 36751672; PubMed Central PMCID: PMC9896600","journal-title":"Neuro-Oncol Adv"},{"issue":"3","key":"12216_CR53","doi-asserted-by":"publisher","first-page":"102676","DOI":"10.1016\/j.omtn.2025.102676","volume":"36","author":"OK Dagher","year":"2025","unstructured":"Dagher OK, Pedard M, Bedoya DM, Brookens SK, Migliorini D, Posey AD (2025) Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma. Mol Ther Nucleic Acids 36(3):102676. https:\/\/doi.org\/10.1016\/j.omtn.2025.102676 PubMed PMID: 40896578; PubMed Central PMCID: PMC12397939","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"12216_CR54","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D et al (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012. https:\/\/doi.org\/10.1038\/s41591-024-02875-1 PubMed PMID: 38454126; PubMed Central PMCID: PMC11031404","journal-title":"Nat Med"},{"key":"12216_CR55","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.omto.2022.01.011","volume":"24","author":"L Chen","year":"2022","unstructured":"Chen L, Zhou C, Chen Q, Shang J, Liu Z, Guo Y et al (2022) Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Mol Ther Oncolytics 24:522\u2013534. https:\/\/doi.org\/10.1016\/j.omto.2022.01.011 PubMed PMID: 35229030; PubMed Central PMCID: PMC8851082","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"12216_CR56","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1186\/s12967-024-05650-5","volume":"22","author":"A Reale","year":"2024","unstructured":"Reale A, Gatta A, Shaik AKB, Shallak M, Chiaravalli AM, Cerati M et al (2024) An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma. J Transl Med 22(1):862. https:\/\/doi.org\/10.1186\/s12967-024-05650-5 PubMed PMID: 39334370; PubMed Central PMCID: PMC11430576","journal-title":"J Transl Med"},{"issue":"10","key":"12216_CR57","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19(10):1264\u20131272. https:\/\/doi.org\/10.1038\/nm.3337 PubMed PMID: 24056773; PubMed Central PMCID: PMC3840724","journal-title":"Nat Med"},{"key":"12216_CR58","doi-asserted-by":"publisher","first-page":"719836","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N et al (2021) Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol 11:719836. https:\/\/doi.org\/10.3389\/fonc.2021.719836 PubMed PMID: 34476218; PubMed Central PMCID: PMC8406857","journal-title":"Front Oncol"},{"key":"12216_CR59","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B (2018) Targeting VEGF\/VEGFR to Modulate Antitumor Immunity. Front Immunol 9:978. https:\/\/doi.org\/10.3389\/fimmu.2018.00978 PubMed PMID: 29774034; PubMed Central PMCID: PMC5943566","journal-title":"Front Immunol"},{"issue":"3","key":"12216_CR60","doi-asserted-by":"publisher","first-page":"e005583","DOI":"10.1136\/jitc-2022-005583","volume":"11","author":"X Dong","year":"2023","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S et al (2023) Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer 11(3):e005583. https:\/\/doi.org\/10.1136\/jitc-2022-005583 PubMed PMID: 36898734; PubMed Central PMCID: PMC10008211","journal-title":"J Immunother Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12216-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:39:46Z","timestamp":1782859186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12216"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12216-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1049"}}